Opening Asia for Russia

Injection form of the drug "Areplivir" was registered in Russia

13.11.2021 132 просмотров

The first domestic injectable drug against COVID-19 "Areplivir" was registered.

The first domestic direct-acting injectable drug for the treatment of COVID-19, Areplivir, has been registered and will begin to enter hospitals by the end of 2021, the press service of the developer, Promomed Group, told TASS.

“The first domestic intravenous antiviral The direct-acting drug Areplivir (Favipiravir) has received a registration certificate and will be delivered to hospitals in all regions by the end of the year. With its development, the Promomed Group of Companies responded to the acute need of domestic healthcare for hospital COVID-19 therapies,” the press service said. will start in December 2021. The company noted that Promomed was the first in the world to create an injectable form of favipiravir, despite the fact that the substance is an insoluble powder. A multicenter clinical study led by Academician of the Russian Academy of Sciences Dmitry Pushkar confirmed the efficacy and safety of the new drug when used in hospitals.

The oral form of Areplivir is included in the current recommendations for both outpatient and inpatient stages. It is expected that the injectable form will also be included in the recommendations as more effective for the treatment of hospitalized patients. The final decision will be made by the Ministry of Health of the Russian Federation during the next revision of temporary guidelines for the prevention, diagnosis and treatment of a new coronavirus infection, Promomed stressed. According to the chief pulmonologist of the Ministry of Health of the Russian Federation, Corresponding Member of the Russian Academy of Sciences Sergey Avdeev, until now the only antiviral drug for parenteral administration has been a foreign drug, not only expensive, but also inaccessible.

effective domestic antiviral drug for parenteral administration, while being widely available, can turn the tide in the fight against the pandemic. The injectable form of the drug is characterized not only by 100% bioavailability, but also by more intensive penetration and distribution in cells, a longer retention of therapeutic concentration in tissues, as well as an improved safety profile. This should significantly increase the effectiveness of ongoing treatment at the hospital stage,” said Sergey Avdeev.

The company also recalled that during a recent meeting, Russian President Vladimir Putin announced the emergence of new domestic drugs for fight against COVID-19. One of the first such drugs was the injectable Areplivir.

Новости партнёров